Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 9/20 | 0.62 |
| ▸ | DHFR known ✓ | P00374 | 7/20 | 0.62 |
| ▸ | TYMS known ✓ | P04818 | 6/20 | 0.62 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.62 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.62 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.62 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.62 |
| ▸ | ATIC | P31939 | 2/20 | 0.62 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.62 |
| ▸ | FRK | P42685 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL4603766 | 0.99 | GART (0.61) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2190320 | 0.99 | GART (0.61) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL572065 | 0.89 | GART (0.73) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL6034765 | 0.89 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7969 | 0.89 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2549428 | 0.89 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7968 | 0.89 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1934793 | 0.88 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15648731 | 0.88 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124673 | 0.88 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009198-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2024-01-11 | — | — | US | claimed |
| US-20240009199-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2024-01-11 | — | — | US | claimed |
| US-20230414623-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | claimed |
| US-20230390295-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2023-12-07 | — | — | US | claimed |
| US-11793813-B2 | Pemetrexed formulations | EAGLE PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | claimed |
| US-20230000874-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | US | claimed |
| US-20220409623-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. (US) | 2022-12-29 | — | — | US | claimed |
| US-20220409624-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. (US) | 2022-12-29 | — | — | US | claimed |
| CN-115197224-A | Novel crystal form of pemetrexed diacid and preparation method thereof | 齐鲁制药有限公司 | 2022-10-18 | — | — | CN | claimed |
| US-20220151923-A1 | STABLE LIQUID COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2022-05-19 | — | — | US | claimed |
| US-20090012294-A1 | Highly pure pemetrexed Diacid and processes for the preparation thereof | SICOR INC. | 2009-01-08 | — | — | US | claimed |
| WO-2008124485-A2 | SOLID FORMS OF PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-10-16 | — | — | WO | claimed |
| EP-1945645-A1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND PROCESSES FOR THE PREPARATION THEREOF | Sicor, Inc. (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1943252-A2 | PROCESSES FOR THE PREPARATION OF LYOPHILIZED PHARMACEUTICALLY ACCEPTABLE SALTS OF PEMETREXED DIACID | Sicor, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1934226-A2 | HIGHLY PURE PEMETREXED DIACID AND PROCESSES FOR THE PREPARATION THEREOF | Sicor, Inc. (US) | 2008-06-25 | — | — | EP | claimed |
| US-20080139810-A1 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-06-12 | — | — | US | claimed |
| WO-2008021410-A2 | HIGHLY PURE PEMETREXED DIACID AND PROCESSES FOR THE PREPARATION THEREOF | SICOR INC. (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2008021405-A1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND PROCESSES FOR THE PREPARATION THEREOF | SICOR INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-20080045711-A1 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-02-21 | — | — | US | claimed |
| WO-2008021411-A2 | PROCESSES FOR THE PREPARATION OF LYOPHILIZED PHARMACEUTICALLY ACCEPTABLE SALTS OF PEMETREXED DIACID | SICOR INC. (US) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009199-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20090012294-A1 | Highly pure pemetrexed Diacid and processes for the preparation thereof | DCTD, DPYD, TYMP | GART 38/4885DHFR 6/4885TYMS 4/4885 |
| US-11793813-B2 | Pemetrexed formulations | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20240009198-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20080045711-A1 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | DCTD, DPYD, TYMP | GART 37/4885DHFR 6/4885TYMS 9/4885 |
| US-20230414623-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20220409624-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20220409623-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20230390295-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20220151923-A1 | STABLE LIQUID COMPOSITIONS OF PEMETREXED | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DCTD, PDCD5 | GART 130/4885DHFR 101/4885TYMS 20/4885 |
| US-20230000874-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | GART 241/4885DHFR 3/4885TYMS 4/4885 |
| US-20080139810-A1 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | DCTD, DPYD, PDCD2L | GART 77/4885DHFR 19/4885TYMS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.